Vitiligo Clinical Trial
Official title:
Efficacy of Upadacitinib After Autologous Non-cultured Epidermal Cell Suspension Transplantation in Vitiligo Participants -- a Pilot, Random, Observer Blinded, Comparative Study
NCT number | NCT06454461 |
Other study ID # | SLi |
Secondary ID | |
Status | Not yet recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 1, 2024 |
Est. completion date | June 1, 2029 |
The goal of this clinical trial is to investigate the efficacy of upadacitinib after NECS in participants with vitiligo. The main question it aims to answer is: whether the short time use of upadacitinib after NECS will improve NECS efficacy. Participants in the experimental group will receive upadacitinib after NECS, while Participants in the control group will receive NECS only.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | June 1, 2029 |
Est. primary completion date | June 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Participants who can sign the informed consent. 2. Participants aged 18-60 years (both men and women) at the time of signing the informed consent. 3. Non-segmented vitiligo 4. Vitiligo affected area should meet the following two criteria: (1) containing the target area (relatively flat vitiligo lesions except of the hands and feet, perineum, lips, joints, perianal); (2) total BSA involvement =30% 5. Clinically stable for more than one year (stable refers to the original lesion no longer expanding and no new lesions appearing). 6. All fertile women had to be willing to use at least one highly effective method of contraception from the time they signed informed consent through the final follow-up visit. 7. Participants must be willing and able to adhere to scheduled visits and scheduled treatments, laboratory tests, and other study procedures. Exclusion Criteria: 1. Any active skin lesions (e.g. psoriasis, dermatitis, skin ulceration, etc.) or skin infections (bacterial, fungal, viral, etc.) which may interfere with the assessment of vitiligo at screening. 2. Participants had a clinically significant infection (requiring hospitalization and parenteral treatment with antibiotics, antiviral agents, or antifungal agents for more than 3 days) within one month of the screening period or an active infection for which they were receiving treatment during the screening period. 3. Infected with HBV or HCV or HIV or syphilis. 4. Participants had active Tuberculosis or were receiving anti-Tuberculosis treatment, or had received anti-Tuberculosis treatment within 1 year. 5. Hepatic dysfunction (Total bilirubin = 2 × ULN, AST=2 × ULN, ALT = 2 × ULN) at screening. 6. Renal impairment ( eGFR of <45 mL/min or receiving dialysis) at screening 7. Participants with malignancy or with a history of malignancy other than adequately treated or resected nonmetastatic basal cell carcinoma or squamous cell carcinoma. 8. Participants with current thyroid disease or undergoing thyroid replacement therapy. 9. Participants with a history of mental illness, such as anxiety or depression, who were assessed by the investigator to be unfit to participate in the study. 10. Pregnant or lactating female participants. 11. Participants who received any laser or phototherapy for vitiligo within 4 weeks before baseline. 12. Participants who received oral or systemic medications (e.g., glucocorticoids, cyclosporine, methotrexate, tacrolimus, Chinese medicine, etc.) aimed at controlling/improving vitiligo symptoms within 4 weeks before baseline. 13. Participants who had received JAK inhibitor therapy (including, but not limited to Ruxolitinib, Tofacitinib, Baricitinib, Upadacinib, etc.) within 12 weeks or 5 half-lives before baseline, whichever was longer. 14. Participants who had used any biologic agent within 12 weeks or 5 half-lives before baseline, whichever was longer. 15. Participants who had been enrolled in another intervention clinical trial within 4 weeks before the baseline visit or who were within 5 half-lives of the last dose of the intervention drug at baseline. 16. Any other condition that the investigator considered might render the subject ineligible for inclusion in the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Jilin University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | T-VASI | Percentage of change from baseline in target lesion Vitiligo Area Scoring Index (T-VASI) at 6 months | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05298033 -
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
|
Phase 2 | |
Recruiting |
NCT05872477 -
Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas
|
Phase 2 | |
Terminated |
NCT04374435 -
Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo
|
N/A | |
Completed |
NCT04103060 -
Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
|
Phase 2 | |
Terminated |
NCT04271501 -
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
Completed |
NCT04530344 -
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
|
Phase 3 | |
Not yet recruiting |
NCT05008887 -
Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo
|
Phase 4 | |
Terminated |
NCT02191748 -
Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo
|
Phase 2/Phase 3 | |
Completed |
NCT01382589 -
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
|
Phase 2 | |
Terminated |
NCT01262547 -
A New Micrografting Technique for Vitiligo
|
Phase 2 | |
Active, not recruiting |
NCT04971200 -
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
|
Early Phase 1 | |
Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
Completed |
NCT04547998 -
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
Not yet recruiting |
NCT04039451 -
Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
|
||
Not yet recruiting |
NCT03611348 -
Microneedling and Latanoprost in Acrofacial Vitiligo
|
Phase 2/Phase 3 | |
Recruiting |
NCT03199664 -
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
|
Phase 4 | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT03249064 -
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
|
N/A | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 |